Daiwa Securities Group Inc. Has $5.08 Million Stock Holdings in Edwards Lifesciences Co. (NYSE:EW)

Daiwa Securities Group Inc. increased its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 8.8% during the 4th quarter, Holdings Channel.com reports. The fund owned 66,570 shares of the medical research company’s stock after acquiring an additional 5,375 shares during the period. Daiwa Securities Group Inc.’s holdings in Edwards Lifesciences were worth $5,076,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Castleview Partners LLC acquired a new stake in Edwards Lifesciences during the first quarter valued at approximately $25,000. Compass Wealth Management LLC acquired a new stake in Edwards Lifesciences in the 4th quarter valued at $31,000. Turtle Creek Wealth Advisors LLC acquired a new stake in Edwards Lifesciences in the 4th quarter valued at $34,000. Janiczek Wealth Management LLC grew its position in Edwards Lifesciences by 108.6% in the third quarter. Janiczek Wealth Management LLC now owns 582 shares of the medical research company’s stock valued at $40,000 after acquiring an additional 303 shares during the period. Finally, Operose Advisors LLC raised its stake in Edwards Lifesciences by 247.0% during the third quarter. Operose Advisors LLC now owns 635 shares of the medical research company’s stock worth $44,000 after acquiring an additional 452 shares in the last quarter. Institutional investors own 79.46% of the company’s stock.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 7,255 shares of the stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $78.29, for a total value of $567,993.95. Following the transaction, the chief financial officer now owns 19,248 shares of the company’s stock, valued at $1,506,925.92. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other news, Director Heisz Leslie Stone sold 7,056 shares of Edwards Lifesciences stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $86.45, for a total transaction of $609,991.20. Following the transaction, the director now directly owns 26,980 shares of the company’s stock, valued at $2,332,421. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO Scott B. Ullem sold 7,255 shares of the company’s stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $78.29, for a total transaction of $567,993.95. Following the completion of the sale, the chief financial officer now owns 19,248 shares of the company’s stock, valued at approximately $1,506,925.92. The disclosure for this sale can be found here. In the last 90 days, insiders sold 194,004 shares of company stock worth $17,166,254. Insiders own 1.29% of the company’s stock.

Edwards Lifesciences Price Performance

Edwards Lifesciences stock opened at $85.94 on Friday. The stock has a market cap of $51.73 billion, a price-to-earnings ratio of 37.37, a P/E/G ratio of 4.29 and a beta of 1.05. Edwards Lifesciences Co. has a 12-month low of $60.57 and a 12-month high of $96.12. The company has a quick ratio of 2.40, a current ratio of 3.38 and a debt-to-equity ratio of 0.09. The business’s 50-day simple moving average is $90.15 and its 200 day simple moving average is $78.31.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Tuesday, February 6th. The medical research company reported $0.64 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.64. The company had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.50 billion. Edwards Lifesciences had a net margin of 23.35% and a return on equity of 23.56%. The company’s revenue for the quarter was up 13.3% on a year-over-year basis. During the same quarter last year, the firm earned $0.64 EPS. As a group, research analysts anticipate that Edwards Lifesciences Co. will post 2.76 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the stock. Mizuho boosted their target price on shares of Edwards Lifesciences from $95.00 to $105.00 and gave the company a “buy” rating in a research note on Thursday, April 11th. OTR Global raised shares of Edwards Lifesciences from a “mixed” rating to a “positive” rating in a research note on Tuesday, March 26th. Morgan Stanley lifted their target price on shares of Edwards Lifesciences from $95.00 to $103.00 and gave the company an “overweight” rating in a research note on Thursday, March 21st. Truist Financial increased their price target on Edwards Lifesciences from $78.00 to $84.00 and gave the stock a “buy” rating in a research report on Friday, December 22nd. Finally, Stifel Nicolaus lifted their price objective on Edwards Lifesciences from $70.00 to $83.00 and gave the company a “hold” rating in a research report on Wednesday, February 7th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and ten have given a buy rating to the company. According to MarketBeat.com, Edwards Lifesciences currently has a consensus rating of “Moderate Buy” and an average target price of $91.73.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.